Skip to main content
Erschienen in: Supportive Care in Cancer 12/2007

01.12.2007 | Original Article

Patterns of use of vascular access devices in patients undergoing hematopoietic stem cell transplantation: results of an international survey

verfasst von: Juan J. Toro, Manuel Morales, Fausto Loberiza, Jose L. Ochoa-Bayona, Cesar O. Freytes

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

Introduction

There is limited information regarding of use of vascular access devices (VAD) in patients undergoing hematopoietic stem cell transplantation (HSCT). The frequent use of VAD in HSCT and its potential to cause morbidity requires understanding of the general use of VAD in HSCT.

Materials and methods

A World Wide Web-based 19-item questionnaire was designed to determine the patterns of use of VAD in patients undergoing HSCT. The questionnaire was sent via electronic mail to the directors of HSCT programs throughout the world.

Results

Of the 445 centers surveyed, 163 centers replied for a response rate of 37%. The most commonly used catheter for autologous peripheral blood stem cell (PBSC) harvest is the dual-lumen plasmapheresis/hemodialysis (62%). Of the institutions, 58% utilize the same catheter used for PBSC harvest to provide vascular access support during the transplant. Catheter-related blood stream infection (36%) and withdrawal occlusion (31%) were the most frequently encountered complications of VAD. Of the centers, 65% have established criteria for VAD removal when infection is suspected and 48% when occlusion is suspected.

Discussion

Our study demonstrated that there are similarities in the utilization of VAD but also wide differences in the standard procedures for the insertion and care of VAD in the transplant setting. More comprehensive studies are needed to assess the use of central venous catheters in transplant recipients. Important areas for future research include the impact of VAD utilization on the quality of life of transplant recipients and the final consequences of VAD complications.
Literatur
1.
Zurück zum Zitat Couban S, Goodyear M, Burnell B, Dolan S, Wasi P, Barnes D, MacLeod D, Burton E, Andreou P, Anderson DR (2005) Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23:4063–4069PubMedCrossRef Couban S, Goodyear M, Burnell B, Dolan S, Wasi P, Barnes D, MacLeod D, Burton E, Andreou P, Anderson DR (2005) Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23:4063–4069PubMedCrossRef
2.
Zurück zum Zitat Cunningham MS, White B, Hollywood D, O’Donell J (2006) Primary thromboprophylaxis for cancer patients with central venous catheters—a reappraisal of the evidence. Br J Cancer 94:189–194PubMedCrossRef Cunningham MS, White B, Hollywood D, O’Donell J (2006) Primary thromboprophylaxis for cancer patients with central venous catheters—a reappraisal of the evidence. Br J Cancer 94:189–194PubMedCrossRef
3.
Zurück zum Zitat Gaitini D, Beck-Razi, Haim N, Brenner B (2006) Prevalence of upper extremity deep venous thrombosis diagnosed by color Doppler duplex sonography in cancer patients with central venous catheters. J Ultrasound Med 25:1297–1303PubMed Gaitini D, Beck-Razi, Haim N, Brenner B (2006) Prevalence of upper extremity deep venous thrombosis diagnosed by color Doppler duplex sonography in cancer patients with central venous catheters. J Ultrasound Med 25:1297–1303PubMed
4.
Zurück zum Zitat Hachem R, Raad I (2002) Prevention and management of long-term catheter related infections in cancer patients. Cancer Invest 20:1105–1113PubMedCrossRef Hachem R, Raad I (2002) Prevention and management of long-term catheter related infections in cancer patients. Cancer Invest 20:1105–1113PubMedCrossRef
5.
Zurück zum Zitat Johansson E, Sollen Hansson M, Nilson A, Engervall P (1999) Vascular devices used during harvest of peripheral blood stem cells: high complication rate in patients with long-term dialysis central venous catheter. Bone Marrow Transplant 24:793–797PubMedCrossRef Johansson E, Sollen Hansson M, Nilson A, Engervall P (1999) Vascular devices used during harvest of peripheral blood stem cells: high complication rate in patients with long-term dialysis central venous catheter. Bone Marrow Transplant 24:793–797PubMedCrossRef
6.
Zurück zum Zitat Linenberger ML (2006) Catheter-related thrombosis: risks, diagnosis and management. J Natl Compr Cancer Netw 4:889–901 Linenberger ML (2006) Catheter-related thrombosis: risks, diagnosis and management. J Natl Compr Cancer Netw 4:889–901
7.
Zurück zum Zitat McDermott MK (1995) Patient education and compliance issues associated with access devices. Semin Oncol Nurs 11:221–226PubMedCrossRef McDermott MK (1995) Patient education and compliance issues associated with access devices. Semin Oncol Nurs 11:221–226PubMedCrossRef
8.
Zurück zum Zitat Mey U, Glasmacher A, Hahn C, Gorschluter M, Ziske C, Mergerlsberg M, Sauerbruch T, Schmidt-Wolf IG (2003) Evaluation of an ultrasound-guided technique for central venous access via the internal jugular vein in 493 patients. Support Care Cancer 11:148–155PubMed Mey U, Glasmacher A, Hahn C, Gorschluter M, Ziske C, Mergerlsberg M, Sauerbruch T, Schmidt-Wolf IG (2003) Evaluation of an ultrasound-guided technique for central venous access via the internal jugular vein in 493 patients. Support Care Cancer 11:148–155PubMed
9.
Zurück zum Zitat Morales M, Dorta J (1994) Percutaneous insertion of Hickman catheters while the patient is in bed: a simplification of the technique. Support Care Cancer 2:270–271PubMedCrossRef Morales M, Dorta J (1994) Percutaneous insertion of Hickman catheters while the patient is in bed: a simplification of the technique. Support Care Cancer 2:270–271PubMedCrossRef
10.
Zurück zum Zitat O’Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Randolph A, Weinstein RA; Healthcare Infection Control Practices Advisory Committee (2002). Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 23:759–769PubMedCrossRef O’Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Randolph A, Weinstein RA; Healthcare Infection Control Practices Advisory Committee (2002). Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 23:759–769PubMedCrossRef
11.
Zurück zum Zitat Raaf JH (1994) Administration of chemotherapeutic agents. Techniques and controversies. Support Care Cancer 2:335–346PubMedCrossRef Raaf JH (1994) Administration of chemotherapeutic agents. Techniques and controversies. Support Care Cancer 2:335–346PubMedCrossRef
12.
Zurück zum Zitat Restrepo A, Devore P, Encarnacion CE, Wholey MH, Schneider D, Callander NS, Ferral H, Postoak D, Anderson JE, Walsh T, Padayao G, Gokmen E, Ehsan A, Ochoa L, Neumon B, West G, Restrepo MI, Przykucki J, Patterson J, Freytes CO (2002) Performance of a hybrid central venous catheter utilized for both peripheral blood stem cell harvest and transplant support of patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 30:389–395PubMedCrossRef Restrepo A, Devore P, Encarnacion CE, Wholey MH, Schneider D, Callander NS, Ferral H, Postoak D, Anderson JE, Walsh T, Padayao G, Gokmen E, Ehsan A, Ochoa L, Neumon B, West G, Restrepo MI, Przykucki J, Patterson J, Freytes CO (2002) Performance of a hybrid central venous catheter utilized for both peripheral blood stem cell harvest and transplant support of patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 30:389–395PubMedCrossRef
13.
Zurück zum Zitat Sadler DJ, McCarthy M, Saliken JC, So CB, Klassen J, Selinger S, Grey RR (2000) Image-guided central venous catheter placement for apheresis in allogeneic stem cell donors. J Clin Apher 15:173–175PubMedCrossRef Sadler DJ, McCarthy M, Saliken JC, So CB, Klassen J, Selinger S, Grey RR (2000) Image-guided central venous catheter placement for apheresis in allogeneic stem cell donors. J Clin Apher 15:173–175PubMedCrossRef
14.
Zurück zum Zitat Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21:3665–3675PubMedCrossRef Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21:3665–3675PubMedCrossRef
15.
Zurück zum Zitat Verso M, Agnelli G, Bertoglio S, DiSoma FC, Paoletti F, Ageno W, Bazzan M, Parise P, Quintavalla R, Naglieri E, Santoro A, Imberti D, Soraru M, Mosca S (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23:4057–4062PubMedCrossRef Verso M, Agnelli G, Bertoglio S, DiSoma FC, Paoletti F, Ageno W, Bazzan M, Parise P, Quintavalla R, Naglieri E, Santoro A, Imberti D, Soraru M, Mosca S (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23:4057–4062PubMedCrossRef
Metadaten
Titel
Patterns of use of vascular access devices in patients undergoing hematopoietic stem cell transplantation: results of an international survey
verfasst von
Juan J. Toro
Manuel Morales
Fausto Loberiza
Jose L. Ochoa-Bayona
Cesar O. Freytes
Publikationsdatum
01.12.2007
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2007
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0261-8

Weitere Artikel der Ausgabe 12/2007

Supportive Care in Cancer 12/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.